Pfizer buys Array Biopharma for $ 48 per share in cash



[ad_1]

Pfizer announced Monday it had agreed to acquire Array Biopharma for $ 10.64 billion, which would give it access to its anti-cancer drugs.

The cash deal for $ 48 per share of Array represents a premium of about 62% over the closing price of the stock on Friday.

The boards of directors of both companies have approved the merger.

It's breaking news. Please check again for updates.

[ad_2]
Source link